SPRCSciSparc Ltd.

Nasdaq scisparc.com


$ 0.29 $ -0.01 (-4.57 %)    

Tuesday, 17-Sep-2024 14:10:27 EDT
QQQ $ 472.68 $ -3.29 (-0.69 %)
DIA $ 417.40 $ -0.58 (-0.14 %)
SPY $ 562.45 $ -2.68 (-0.47 %)
TLT $ 100.88 $ -0.51 (-0.5 %)
GLD $ 237.49 $ -0.49 (-0.21 %)
$ 0.3116
$ 0.30
$ 0.31 x 1,200
$ 0.41 x 400
$ 0.28 - $ 0.30
$ 0.28 - $ 14.22
6,470,626
na
220,202
$ 1.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clearmind-medicine-files-international-patent-for-ibogaine-combination-therapy

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.

 reported-august-28-scisparc-files-for-sale-of-up-to-21m-ordinary-shares-under-20m-sepa-agreement-shares-priced-at-97-of-market-value-may-receive-up-to-882m

Reported August 28: SciSparc Files For Sale Of Up To 21M Ordinary Shares Under $20M SEPA Agreement; Shares Priced At 97% Of Mar...

 scisparc-grants-global-rights-for-pain-therapy-to-polyrizon-ltd-in-agreement-worth-up-to-6m-3m-in-polyrizon-securities-as-well-as-potential-milestone-fees-of-3m-in-cash

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential mileston...

 scisparc-submits-ind-application-to-the-fda-for-sci-110-phase-iib-clinical-trial-for-patients-with-tourette-syndrome

SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School...

 autism-cbd-trial-on-children-advances-as-israeli-company-enrolls-first-five-patients

SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing cl...

 israel-based-biotech-penny-stock-scisparc-outlicenses-its-cannabinoid-pain-therapy

SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milesto...

 scisparc-finalizes-exclusive-global-out-licensing-agreement-with-polyrizon-for-sci-160-pain-therapy-program-valued-at-3m

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milest...

 scisparc-reports-courts-approval-of-automaxs-petition-to-convene-special-class-meetings-of-shareholders-to-approve-merger

SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's...

Core News & Articles

SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by co...

 scisparc-announces-mitocarex-confirms-potential-significant-role-of-its-drug-target-in-nsclc

The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION